Climb Bio Inc (CLYM) News & EventsCLYMClimb Bio Inc

Climb Bio Set for Defining Milestones in 2026

"2026 is proving to be a defining year for Climb Bio, and I am thrilled by the team's execution," said Aoife Brennan, President and Chief Executive Officer of Climb Bio. "We achieved important milestones for both budoprutug and CLYM116 over the past few months, and that momentum continues into the second half of the year with further data readouts across all four of our ongoing trials and the initiation of a Phase 2 trial of CLYM116 in IgAN patients. Currently at the forefront, I look forward to sharing initial Phase 1 data from CLYM116 in our September R&D Spotlight, where we will further highlight its potential as a best-in-class anti-APRIL antibody and provide additional details on our development strategy. With our continued progress across our pipeline, and supported by our strengthened balance sheet, we are well positioned to continue to execute on our strategic priorities and rapidly advance both programs toward pivotal development, setting the stage for what we believe will be an exciting 2027 for Climb."

Climb Bio Announces Initial Data on Budoprutug

Climb Bio announced initial data from the ongoing Phase 1b portion of its Phase 1b/2a study evaluating budoprutug, an anti-CD19 monoclonal antibody, in adults with primary immune thrombocytopenia demonstrating an encouraging safety and tolerability profile, robust B-cell depletion, and meaningful platelet responses in heavily pretreated patients. The initial data are being presented at the European Hematology Association, or EHA, Congress 2026, which is being held on June 11-14 in Stockholm, Sweden. The ongoing Phase 1b/2a study is evaluating budoprutug in patients with primary ITP to inform dose and regimen selection and assess safety and the depth and duration of platelet response and B-cell depletion. Initial safety and efficacy data are available from the 250 mg cohort, and initial safety data are available from the 500 mg cohort. Enrollment in the 1000 mg cohort is ongoing. The Phase 1b portion of the Phase 1b/2a study is evaluating three ascending doses of intravenous budoprutug, administered in two doses 14 days apart, in adults with primary ITP who have received at least one prior therapy. As of June 1, 15 patients had been enrolled across the 250 mg and 500 mg dose cohorts, median follow-up was 38 weeks and 12 weeks for the 250 mg and 500 mg cohorts respectively. Patients enrolled were heavily pretreated, with a median of 6 to 7.5 prior lines of therapy and disease duration ranging from 0.5 to 40 years. Budoprutug was generally well tolerated at both the 250 mg and 500 mg dose levels, with no serious adverse events, no treatment discontinuations due to adverse events, and no infusion related reactions; all adverse events were Grade 1 to Grade 2. In the 250 mg dose cohort, B-cell levels were depleted by an average of over 90% by Week 4 and mean platelet count increased by 111,000 platelets/microL at Week 24. Durable platelet responses were achieved in four out of six patients in the 250 mg dose cohort, with two out of six patients experiencing platelet levels greater than100 x 103/microL for over 24 weeks. Of the four patients who had previously been treated with rituximab, three responded to treatment with budoprutug, two with durable and complete responses Results to date support continued clinical evaluation of budoprutug in ITP; enrollment in the 1000 mg cohort is ongoing.

Selling Stockholder Plans to Sell Up to 11.59M Shares

This filing relates to the offer and sale from time to time by the selling stockholder of up to 11.59M shares of common stock. The company is not selling any shares under this prospectus and will not receive any of the proceeds from the sale of shares by the selling stockholders.